Welcome!

News Feed Item

Diabetes: Battle for ascendancy escalates in expanding market - KOL Insight





 

 

 

NEW YORK, Aug. 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:



Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight
http://www.reportlinker.com/p01601323/Diabetes-Battle-for-ascendancy-escalates-in-expanding-market-–-KOL-Insight.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology


Diabetes is one of the few disease areas that has retained its market value despite the entry of generics, the rise in drug prices and prevalence of the disease has allowed drug sales to soar to a worldwide value of $34.1 billion in 2012. While barriers to entry remain high with added scrutiny over cardiovascular and other safety risks, evident by Tresiba's (insulin degludec; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma.

Competition in the major drug segments are intense with Sanofi's basal insulin Lantus (insulin glargine), Novo's prandial insulin NovoRapid/NovoLog (insulin aspart), Merck's DPP-IV Januvia (sitagliptin), and Novo's GLP-1 Victoza (liraglutide) leading the way in their respective classes with best in class efficacy and safety. In addition to these clinical advantages, more convenient administration devices and strong marketing has helped them stand out from the competition.

While Novo Nordisk, Sanofi and Merck look set to protect their franchises with exciting pipeline therapies, Key Opinion Leaders interviewed by FirstWord note that there are a number of unmet needs in diabetes treatment and management. Companies that can address these needs and differentiate their products from existing players will see significant traction in this lucrative indication. This is evident from the successful launches of the novel SGLT-2 inhibitors- Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) and Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca), in the US and EU. In addition, therapies showing significant incremental advances also have potential to usurp market share from the gold standard treatments.

'Therapy Trends: Diabetes' is compiled from exclusive, in-depth interviews with the world's leading Key Opinion Leaders in diabetes. It identifies and analyses the major factors, advances and trends currently influencing the diabetes treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future Diabetes management.

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the diabetes disease area, and their scientific standing and clinical experience. Our unique KOL scoring system identifies those thought leaders with the greatest insight into how diabetes clinical research will shape the future market.


Key Benefits

Diabetes: Battle for ascendancy escalates in expanding market examines the most prominent insights gained from the field's key opinion leaders. The results of FirstWord's research and analysis will help you to:
- Comprehend the current trends driving and shaping the global diabetes market

- Understand the future landscape and how new drug classes will fit into the treatment algorithm

- Compare and contrast the clinical profile of the insulins, DPP-IV, GLP-1 and SGLT-2 classes and assess their competitive strengths and weaknesses

- Assess the commercial and clinical potential of the next generation pipeline drugs, biosimilars, and existing therapies.

- Appreciate KOL calls for novel therapies and understand the commercial threat and opportunity for current products.

- Develop positioning strategies based on KOL insight

- Identify critical areas of unmet clinical need and opportunities for better disease management

- Evaluate the performance of companies with the most robust new product pipelines

- Recognise the key factors KOLs predict will drive future treatment trends


Critical questions answered

Diabetes: Battle for ascendancy escalates in expanding market answers key questions including:

- How might new therapies impact on the current first-line treatments?
- What are the current unmet needs and major challenges in diabetes treatment?
- What are the most promising late-stage classes in development?
- Which therapies are KOLs eagerly awaiting?
- How will the new therapies be positioned against each other in each of the disease segments?
- In what ways could players improve on existing therapies and what impact could this have on prescribing?
- How will treatment of diabetes look in the future?
- How do KOLs think the pricing environment is shaping the uptake of new diabetes treatments?
- What clinical research trends do KOLs predict for future diabetes therapies?


Diabetes Panel of Key Opinion Leaders

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the Diabetes disease area, and their scientific standing and clinical experience. The Diabetes KOL panel assembled for this Therapy Trends research is drawn from North America and Europe:

- Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.
- Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.
- Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.
- Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY
- Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.
- Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department
- Honorary Consultant, Diabetes, University Hospital Leicester, Leicesteshire, UK
- Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
- Professor, Professor of Medicine, Diabetes, Eberhard Karls University, University Hospital of Tuebingen, Germany.
- Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
- Head, Diabeteszentrum Bad Lauterberg, Harz, Germany.
- Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.


Future Event Updates

Dynamic clinical sectors develop. New product approvals/launches, extended indications or unexpected late-stage research failures/withdrawals can have a major impact on the treatment options for clinicians and performance of companies. What does such an event mean for stakeholders?
FirstWord's Therapy Trends Future Event Updates keep you one step ahead. As soon as a significant event has been identified we contact our KOL panelists to get their perspective of the event and what it means. This data is incorporated into the report and re-issued so the event can be seen in its wider market context.
This valuable service is included in the purchase price of the report and is provided for 12 months. You will receive fresh analysis every time a major market event breaks and a fully updated report will be delivered by to you one our consultants within days of each event's occurrence.
Whatever the event, Therapy Trends has the contacts, resources and knowledge to keep you up to date with what the latest market movements mean.


Methodology

This report provides a qualitative overview of the current and future diabetes market. Information was gathered from telephone interviews held with twelve key opinion leaders (KOLs), from across the major diabetes markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also influence the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subjects covered in the interviews included future diagnostic and therapeutic strategies for diabetes, the future of diabetes drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing diabetes drug classes, the cost of newer drugs and other concerns in the therapy area.



Executive summary

Introduction

Methodology

Current diabetes marketplace

Diabetes overview
Diabetes definition
Diabetes segmentation
Epidemiology
Aetiology
Risk factors
Symptoms
Complications of diabetes
Diagnosis
Diabetes treatment
Current treatment landscape
Reimbursement of key diabetes brands
Current marketed therapies
Basal insulins
Prandial insulins
Premixed insulins
Dipeptidyl Peptidase-IV (DPP-IV) inhibitors
Glucagon-like peptide-1 (GLP-1) agonists/analogues
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
Thiazolidinediones (TZD)
Other non-insulin anti-diabetics
Pipeline therapies
Pipeline basal insulins
Pipeline prandial insulins
Pipeline dipeptidyl peptidase-IV (DPP-IV) inhibitors
Pipeline glucagon-like peptide-1 (GLP-1) agonists/analogues
Pipeline sodium-glucose co-transporter 2 (SGLT-2) inhibitors
Other pipeline non-insulin anti-diabetics
Treatment focus
Unmet needs in type 1 diabetes
Unmet needs in type 2 diabetes
Current treatment algorithm- Type2 diabetes
Future treatment algorithm
Future developments in Diabetes

KOL biographies





To order this report:
Pathology Industry:
Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight

__________________________

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and Bi...
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
Serveless Architectures brings the ability to independently scale, deploy and heal based on workloads and move away from monolithic designs. From the front-end, middle-ware and back-end layers, serverless workloads potentially have a larger security risk surface due to the many moving pieces. This talk will focus on key areas to consider for securing end to end, from dev to prod. We will discuss patterns for end to end TLS, session management, scaling to absorb attacks and mitigation techniques.
Contextual Analytics of various threat data provides a deeper understanding of a given threat and enables identification of unknown threat vectors. In his session at @ThingsExpo, David Dufour, Head of Security Architecture, IoT, Webroot, Inc., discussed how through the use of Big Data analytics and deep data correlation across different threat types, it is possible to gain a better understanding of where, how and to what level of danger a malicious actor poses to an organization, and to determin...
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, discussed how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved efficienc...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
Containers, microservices and DevOps are all the rage lately. You can read about how great they are and how they’ll change your life and the industry everywhere. So naturally when we started a new company and were deciding how to architect our app, we went with microservices, containers and DevOps. About now you’re expecting a story of how everything went so smoothly, we’re now pushing out code ten times a day, but the reality is quite different.
"We do one of the best file systems in the world. We learned how to deal with Big Data many years ago and we implemented this knowledge into our software," explained Jakub Ratajczak, Business Development Manager at MooseFS, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, will outline ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and...
You want to start your DevOps journey but where do you begin? Do you say DevOps loudly 5 times while looking in the mirror and it suddenly appears? Do you hire someone? Do you upskill your existing team? Here are some tips to help support your DevOps transformation. Conor Delanbanque has been involved with building & scaling teams in the DevOps space globally. He is the Head of DevOps Practice at MThree Consulting, a global technology consultancy. Conor founded the Future of DevOps Thought Leade...
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...